Log in

NASDAQ:ETNB89bio Stock Price, Forecast & News

+1.24 (+4.13 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $31.25
50-Day Range
MA: $28.73
52-Week Range
Now: $31.25
Volume53,669 shs
Average Volume55,647 shs
Market Capitalization$405.94 million
P/E RatioN/A
Dividend YieldN/A
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate, BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 that is being developed for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.03 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ETNB



Sales & Book Value

Annual SalesN/A
Book Value$6.92 per share



Market Cap$405.94 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable
+1.24 (+4.13 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ETNB News and Ratings via Email

Sign-up to receive the latest news and ratings for ETNB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

89bio (NASDAQ:ETNB) Frequently Asked Questions

How has 89bio's stock been impacted by COVID-19 (Coronavirus)?

89bio's stock was trading at $33.55 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ETNB shares have decreased by 6.9% and is now trading at $31.25.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of 89bio?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for 89bio

When is 89bio's next earnings date?

89bio is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020.
View our earnings forecast for 89bio

How were 89bio's earnings last quarter?

89bio (NASDAQ:ETNB) posted its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.76) earnings per share for the quarter, beating analysts' consensus estimates of ($0.86) by $0.10.
View 89bio's earnings history

What price target have analysts set for ETNB?

7 brokers have issued 12 month price targets for 89bio's stock. Their forecasts range from $33.00 to $60.00. On average, they expect 89bio's share price to reach $49.33 in the next year. This suggests a possible upside of 57.9% from the stock's current price.
View analysts' price targets for 89bio

Has 89bio been receiving favorable news coverage?

News coverage about ETNB stock has been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. 89bio earned a daily sentiment score of -4.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about 89bio

Are investors shorting 89bio?

89bio saw a decrease in short interest during the month of July. As of July 15th, there was short interest totaling 136,000 shares, a decrease of 82.4% from the June 30th total of 774,200 shares. Based on an average trading volume of 92,100 shares, the days-to-cover ratio is currently 1.5 days. Currently, 1.1% of the shares of the company are short sold.
View 89bio's Short Interest

Who are some of 89bio's key competitors?

What other stocks do shareholders of 89bio own?

Who are 89bio's key executives?

89bio's management team includes the following people:
  • Mr. Rohan Palekar, CEO & Director (Age 53)
  • Mr. Ryan Stephen Martins, Chief Financial Officer (Age 42)
  • Mr. Ram Waisbourd, COO & Chief Bus. Officer (Age 52)
  • Mr. Quoc Le-Nguyen, Chief Technical Operations Officer & Head of Quality (Age 51)
  • Dr. Hank Mansbach M.D., Chief Medical Officer (Age 54)

When did 89bio IPO?

(ETNB) raised $70 million in an initial public offering (IPO) on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

What is 89bio's stock symbol?

89bio trades on the NASDAQ under the ticker symbol "ETNB."

How do I buy shares of 89bio?

Shares of ETNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is 89bio's stock price today?

One share of ETNB stock can currently be purchased for approximately $31.25.

How big of a company is 89bio?

89bio has a market capitalization of $405.94 million. The company earns $-57,420,000.00 in net income (profit) each year or ($24.49) on an earnings per share basis. 89bio employs 13 workers across the globe.

What is 89bio's official website?

The official website for 89bio is www.89bio.com.

How can I contact 89bio?

89bio's mailing address is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. The company can be reached via phone at 415-500-4614 or via email at [email protected]

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.